CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

CPhI Worldwide 2019 5 - 7 November 2019, Frankfurt, Germany.
CPhI Worldwide - the world's largest pharma event, taking place in Frankfurt, Germany - released the second part of its annual report focussed on biologicals.

Fittingly, in 2019 BioProduction - which features five concurrent streams of content covering the entire spectrum of biopharmaceutical development and production - will run alongside CPhI Worldwide for the first time, bringing together the entire pharma and biopharma supply chain.

In the report, experts Dawn Ecker, Director of bioTRAK® Database Services with BPTG (BioProcess Technology Group, BDO USA, LLP), and Emil. W. Ciurczak, President of Doramaxx Consulting, explore the near- and medium- term trends in the industry. In particular, the report forecasts the biologics industry's ability to meet and keep pace with future manufacturing capacity concerns, as well as evaluating the current state of quality control in bio - with an emphasis on concerns about CQAs (critical quality attributes) in biosimilars.

Dawn M. Ecker, having analysed the global biopharmaceutical industry's production, predicts that Europe will possess the world’s largest biologics manufacturing capacity within the next four years - a feat currently owned by the USA. Europe’s capacity is growing more quickly year-on-year, and it is expected to increase by 15% come 2023. This growth is helping loosen capacity constraints in the continent in the short term. Asia is also identified as likely to have substantial growth until 2023, with 9% growth per annum. One of the key drivers behind the recent growth in building new capacity has been a number of notable government initiatives and tax incentives in countries such as Ireland, Singapore, and South Korea.

Ecker explains that the growing manufacturing demand - driven by the increasing number of commercially approved biologics - will see the sector significantly expand volumetric capacity. However, much of the new capacity coming online is from CMOs and hybrid companies, who will in turn increase their respective market shares in biologics manufacturing. "Our analysis shows the 2018 mammalian cell culture supply to be nearly 4,400kL and we predict it will grow to nearly 6,400kL by 2023, a 5-year growth rate of 8%. Currently, product companies control over 70% of the installed mammalian cell culture capacity, but this is predicted to drop to 65% by 2023, with CMO capacity increasing 6%, and hybrid companies increasing 1%, respectively." Commented Ecker.

In the current forecast parameters, one of the key variables that could potentially lead to greater shortfalls in available capacity would be a high rate of approvals for certain bio-drugs. Such biologics include those that are being used to treat Alzheimer's disease and cancers, and they may achieve regulatory approval and financial backing from healthcare organisations sooner than expected. "Should several of these large-demand products (e.g PDL/PDL-1 checkpoint inhibitors for broad cancer treatments) obtain regulatory approval and adequate reimbursement by healthcare oversight organizations, a significant increase in demand for manufacturing capacity could occur quickly, potentially leading to a serious capacity shortage." Adding further variables to this prediction, Ecker suggests that projected increases in volumetric demand remain ‘volatile’, seeing as the sector could tilt towards producing ‘more potent products, such as ADCs or bispecific bodies', which require substantially less product demand.

One product group contributing to future capacity demand are biosimilars, Emil Ciurczak explores the impact of the increasing number of biosimilars becoming available, as well as the long-term implications of slight differences in manufacturing approaches. He argues that biosimilar production accentuates the risk of potentially hazardous side products, as, unlike generics, biological impurities could include unknown proteins. As the biology behind rare diseases become more transparent, the biologics developed to treat such diseases - and their synthesis routes - are becoming more complicated. This has significant implications for quality assurance, as both the production and degradation (once in the body) of these molecules can produce a plethora of potentially toxic by-products.

"All impurities in APIs are critical, but with biological impurities (often proteins, not seen previously), the stakes are potentially higher. Not only are there potential long-term carcinogenicity and mutagenicity dangers, but, with unknown proteins, there are also potential immediate allergic reactions. Long-term use of bio-drugs, such as insulin, which could be used for decades, could be of high risk without proper quality control, as even the smallest impurity could do harm to the patient over these extended periods of time." Comments Ciurczak.

He also highlights that biosimilars are just as hard to commercialise as the original products, due to the fact that generic and initiator companies may utilise different biosynthetic pathways, which could result in the formation of different ‘exotic’ by-products. Ciurczak explains: "Competition has arisen for production of biologics from secondary companies, producing the ‘same’ active molecule, but from a different synthesis/bio-expression route. While the major active ingredient may be identical to the patented one, any biological process expresses numerous proteins, each particular to the mode of expression…the most problematic feature of any biosimilar will be the side products and potential side effects."

Looking ahead, Ciurczak predicts that regulators will seek to harmonise their guidances and rules regarding the assessment of critical quality attributes (CQAs) for biologics, with the common goal of expediting production time and therefore time-to-market. He states that we are already seeing such changes beginning to take place - with regulators 'peaking over each other's shoulders when writing guidances and rules', and newer documents becoming increasingly standardised.

CPhI Brand Director Europe, Orhan Caglayan, commented "Our experts suggest that biologics manufacturing is evolving in conjunction with the development of new and exciting bio-products, which we hope will be of fantastic benefit to sufferers of rare diseases. These findings are particularly striking given the introduction of the BioProduction Congress at this year’s event, which will concentrate on the manufacturing and processing of biopharmaceuticals. There has never been a better time for all players within the biopharma space to attend CPhI Worldwide, as the Congress promises to keep you up to date with the latest trends across the biologics supply chain. In particular, the forecast manufacturing capacity constraints may well put CDMOs under pressure, and meeting supply chain partners early at events like CPhI and BioProduction will be essential to securing your supply chain and advancing with products more expeditiously."

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain. CPhI provides an online buyer and supplier directory at CPhI-Online.com.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (5-7, November, 2019 at the Messe in Frankfurt); CPhI & P-MEC India (26-28 November 2019 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); Pharmapack Europe (5-6 February, 2020 at the Paris Expo, Porte de Versailles - Paris, France); CPhI South East Asia (4-6 March, 2020 at the QSNCC - Bangkok, Thailand); CPhI Japan (16-18 March, 2020 at the Big Sight Exhibition Centre - Tokyo, Japan); CPhI North America (05 April - 07 May, 2020 at Pennsylvania Convention Centre - Philadelphia, USA); CPhI and P-MEC China (22-24 June, 2020 at SNIEC - Shanghai, China); CPhI Korea (26-28 August 2020), COEX - Seoul, Korea); CPhI Middle East & Africa (14-16 September, 2020 at the ADNEC - Abu Dhabi, United Arab Emirates)

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...